Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and HCA Healthcare (HCA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and HCA Healthcare (HCA – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vertex Pharmaceuticals (VRTX)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $525.00. The company’s shares closed last Monday at $460.87.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $552.58, which is a 21.3% upside from current levels. In a report issued on March 5, BMO Capital also maintained a Buy rating on the stock with a $600.00 price target.
See the top stocks recommended by analysts >>
HCA Healthcare (HCA)
TD Cowen analyst Ryan Langston assigned a Buy rating to HCA Healthcare yesterday and set a price target of $561.00. The company’s shares closed last Monday at $545.13.
According to TipRanks.com, Langston is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
HCA Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $550.73, representing a 3.7% upside. In a report issued on March 6, TipRanks – OpenAI also upgraded the stock to Buy with a $612.00 price target.
